ArticleScientific reports2023

Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignancies.

Samantha M Goodstal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.